Donald A. Bergstrom - 02 Sep 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role: President, R&D
Signature: /s/ Brian Adams, as attorney-in-fact
Issuer symbol: RLAY
Transactions as of: 02 Sep 2022
Net transactions value: -$104,566
Form type: 4
Filing time: 02 Sep 2022, 17:47:09 UTC
Previous filing: 01 Sep 2022
Next filing: 08 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RLAY	Common Stock	Options Exercise	$20,188	+4,900	+5.5%	$4.12	94,559	02 Sep 2022	Direct	F1, F2
transaction	RLAY	Common Stock	Sale	$124,754	-4,900	-5.2%	$25.46	89,659	02 Sep 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RLAY	Stock Option (Right to Buy)	Options Exercise	$0	-4,900	-3.5%	$0.000000	134,456	02 Sep 2022	Common Stock	4,900	$4.12	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022.
F2	Includes 80,894 shares underlying restricted stock units.
F3	Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.